HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Personalized Stem Cell Therapy to Correct Corneal Defects Due to a Unique Homozygous-Heterozygous Mosaicism of Ectrodactyly-Ectodermal Dysplasia-Clefting Syndrome.

AbstractUNLABELLED:
: Ectrodactyly-ectodermal dysplasia-clefting (EEC) syndrome is a rare autosomal dominant disease caused by mutations in the p63 gene. To date, approximately 40 different p63 mutations have been identified, all heterozygous. No definitive treatments are available to counteract and resolve the progressive corneal degeneration due to a premature aging of limbal epithelial stem cells. Here, we describe a unique case of a young female patient, aged 18 years, with EEC and corneal dysfunction, who was, surprisingly, homozygous for a novel and de novo R311K missense mutation in the p63 gene. A detailed analysis of the degree of somatic mosaicism in leukocytes from peripheral blood and oral mucosal epithelial stem cells (OMESCs) from biopsies of buccal mucosa showed that approximately 80% were homozygous mutant cells and 20% were heterozygous. Cytogenetic and molecular analyses excluded genomic alterations, thus suggesting a de novo mutation followed by an allelic gene conversion of the wild-type allele by de novo mutant allele as a possible mechanism to explain the homozygous condition. R311K-p63 OMESCs were expanded in vitro and heterozygous holoclones selected following clonal analysis. These R311K-p63 OMESCs were able to generate well-organized and stratified epithelia in vitro, resembling the features of healthy tissues. This study supports the rationale for the development of cultured autologous oral mucosal epithelial stem cell sheets obtained by selected heterozygous R311K-p63 stem cells, as an effective and personalized therapy for reconstructing the ocular surface of this unique case of EEC syndrome, thus bypassing gene therapy approaches.
SIGNIFICANCE:
This case demonstrates that in a somatic mosaicism context, a novel homozygous mutation in the p63 gene can arise as a consequence of an allelic gene conversion event, subsequent to a de novo mutation. The heterozygous mutant R311K-p63 stem cells can be isolated by means of clonal analysis and given their good regenerative capacity, they may be used to successfully correct the corneal defects present in this unique case of ectrodactyly-ectodermal dysplasia-clefting syndrome.
AuthorsVanessa Barbaro, Annamaria Assunta Nasti, Paolo Raffa, Angelo Migliorati, Patrizia Nespeca, Stefano Ferrari, Elisa Palumbo, Marina Bertolin, Claudia Breda, Francesco Miceli, Antonella Russo, Luciana Caenazzo, Diego Ponzin, Giorgio Palù, Cristina Parolin, Enzo Di Iorio
JournalStem cells translational medicine (Stem Cells Transl Med) Vol. 5 Issue 8 Pg. 1098-105 (Aug 2016) ISSN: 2157-6564 [Print] England
PMID27151912 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
Copyright©AlphaMed Press.
Chemical References
  • TP63 protein, human
  • Transcription Factors
  • Tumor Suppressor Proteins
Topics
  • 3T3 Cells
  • Adolescent
  • Animals
  • Case-Control Studies
  • Cleft Lip (complications, diagnosis, genetics)
  • Cleft Palate (complications, diagnosis, genetics)
  • Coculture Techniques
  • Corneal Diseases (diagnosis, genetics, surgery)
  • Corneal Transplantation (methods)
  • DNA Mutational Analysis
  • Ectodermal Dysplasia (complications, diagnosis, genetics)
  • Feeder Cells
  • Female
  • Genetic Predisposition to Disease
  • HEK293 Cells
  • Heterozygote
  • Homozygote
  • Humans
  • Mice
  • Mosaicism
  • Mouth Mucosa (cytology, metabolism, transplantation)
  • Mutation, Missense
  • Patient Selection
  • Phenotype
  • Precision Medicine (methods)
  • Predictive Value of Tests
  • Stem Cell Transplantation (methods)
  • Transcription Factors (genetics)
  • Transfection
  • Transplantation, Autologous
  • Tumor Suppressor Proteins (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: